Medical Prosthetics Businesses for Sale and Investment

Business: 4‑patent AI IVF SaaS software integrating with major incubators/microscopes; proprietary 3D‑TCNN delivers embryo grading and implantation probability in ~30 seconds with ~87% accuracy. - Revenue model: Tiered SaaS (per-embryo and annual subscription), plus enterprise on‑prem/hybrid licenses and maintenance; typical ranges: HK$50–100 per embryo, HK$40–80K annual SaaS, and HK$2–5M for on‑prem projects with HK$200–500K yearly support. - Clinical impact: Pregnancy rate uplift from 48.7% to 62.3%; live birth from 44.2% to 56.8%; average transfers reduced from 2.4 → 1.8; ~70% time saved per assessment. - Customers and relationships: IVF centers, fertility clinics, hospital groups, and research labs adopting a staged rollout (observation → decision support → standardized use) with full workflow integration and audit trails. 10–15 centers across Asia are already using our software on an annual subscription model. - Founding team: Reproductive medicine and AI software specialists with ISO 13485/14971/62304, HIPAA, FDA SaMD Class II, EU MDR CE compliance and medical software QMS standards expertise for multi‑site deployment. - Unit economics: Large centers save HK$1.5–3M annually from efficiency gains and better outcomes; ~HK$15,000 cost savings per IVF cycle. - The business is Hong Kong-registered, while the promoter operates from Taiwan. - The company has four permanent employees, with temporary or part-time staff deployed as required.